PLATELET-ACTIVATING-FACTOR CAUSES PULMONARY VASODILATION IN THE RAT
- 1 October 1986
- journal article
- research article
- Published by Elsevier
- Vol. 134 (4) , 757-762
- https://doi.org/10.1164/arrd.1986.134.4.757
Abstract
Although platelet-activating factor (PAF) has generally been found to be a pulmonary pressor substance, its vasoactivity has not been measured at low doses in a preconstricted pulmonary vascular bed. Thus, we examined the effects of low concentrations of PAF on systemic and pulmonary hemodynamics during normoxia and acute hypoxia in conscious, catheterized rats (weighing 250 to 350 g), on hypoxic vasoconstriction in isolated rat lungs, and on norepinephrine-induced constriction in isolated, intact, and endothelium-denuded rat pulmonary arteries. In normoxic rats, injections of 0.001, 0.01, and 1.0 .mu.g PAF/rat given intravenously caused progressively greater, transient systemic hypotension and tachycardia. The 2 higher doses also decreased cardiac output and pulmonary arterial pressure (Ppa). In 5 rats breathing 8% O2, Ppa fell from 36 .+-. 2 to 30 .+-. 2 torr within 1 min of injection of 0.01 .mu.g PAF and did not change (39 .+-. 2 versus 40 .+-. 2 torr) 1 min after 0.25% albumin (vehicle). Total pulmonary resistance was 0.18 .+-. 0.04 torr/ml/min in normoxic rats and 0.19 .+-. 0.04 and 0.28 .+-. 0.06 torr/ml/min, respectively, in hypoxic rats receiving 0.01 .mu.g PAF or vehicle. The PAF (10-10 to 10-8 g/ml) also reversed hypoxic vasoconstriction in isolated lungs perfused at constant low. Lungs perfused with salt solution but not those with blood became rapidly densensitized to PAF-induced vasodilation. After constriction with 10-5 M norepinephrine both acetylcholine (10-7 to 10-6 M) and PAF (10-10 to 10-9 g/ml) dilated intact but not endothelium-denuded pulmonary artery rings. Meclofenamate did not block PAF-induced dilation in either lungs or pulmonary arteries. These results indicate that PAF is a potent, cyclooxygenase-independent, endothelium-dependent, pulmonary vasodilator in the rat. It is unclear whether low concentrations of PAF would have similar effects on the pulmonary circulation of other animals.This publication has 16 references indexed in Scilit:
- Platelet-Activating Factor Raises Airway and Vascular Pressures and Induces Edema in Lungs Perfused with Platelet-Free Solution1–3American Review of Respiratory Disease, 1984
- Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholineEuropean Journal of Pharmacology, 1984
- PREVENTION AND REVERSAL OF HYPOXIC PULMONARY-HYPERTENSION BY CALCIUM-ANTAGONISTSPublished by Elsevier ,1984
- Aortic vascular and atrial responses to (±)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholineBritish Journal of Pharmacology, 1983
- Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.Journal of Clinical Investigation, 1983
- Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogsEuropean Journal of Pharmacology, 1983
- Nonimmunological Production pf Leukotrienes Induced by Platelet-Activating FactorScience, 1982
- DIFFERENTIAL-EFFECTS OF PLATELET DEPLETION ON THE PHYSIOLOGIC ALTERATIONS OF IGE ANAPHYLAXIS AND ACETYL GLYCERYL ETHER PHOSPHORYLCHOLINE INFUSION IN THE RABBITPublished by Elsevier ,1981
- Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesEuropean Journal of Pharmacology, 1980
- RESPIRATORY AND CIRCULATORY ALTERATIONS INDUCED BY ACETYL GLYCERYL ETHER PHOSPHORYLCHOLINE, A MEDIATOR OF IGE ANAPHYLAXIS IN THE RABBITPublished by Elsevier ,1980